In this line, a cut-off level of 0.0045 × 109/l for CD34+MDSC displayed a strong prognostic significance for PFS with a specificity and sensitivity of 92% and 89%, respectively, suggesting that CD34+MDSCs levels could serve as a prognostic biomarker in HL patients. This evidence concerns the gene CD34 and Hodgkins lymphoma.